Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.

Duffy, Jonathan; Marquez, Paige; Dores, Graça M; Ng, Carmen; Su, John; Cano, Maria; Perez-Vilar, Silvia

Duffy, Jonathan; Marquez, Paige; Dores, Graça M; Ng, Carmen; Su, John; Cano, Maria; Perez-Vilar, Silvia.

Afiliação

Duffy J; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Marquez P; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Dores GM; Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Ng C; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Su J; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Cano M; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Perez-Vilar S; Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Open Forum Infect Dis ; 7(12): ofaa516, 2020 Dec.

Article em En | MEDLINE | ID: mdl-33324721

Palavras-chave

meningococcal vaccines; neisseria meningitidis serogroup B; pharmacovigilance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Screening_studies Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google